U.S. Markets closed

Despite Recent Gains, Mirium Shares Still Rated a Buy

Mirium Pharmaceuticals Inc. (NASDAQ:MIRM) shares continue to soar, having nearly tripled since mid-December after it had a successful pre-New Drug Application meeting with the Food and Drug Administration regarding Maralixibat, the company's treatment for pruritus, which is associated with Alagille syndrome.

The stock now trades at more than $23, giving the Foster City, California-based company a market cap of nearly $530 million. Mirium was launched in 2018 with $120 million in Series A funding. Leading the effort was New Enterprise Associates (NEA), followed by Deerfield Management, Frazier, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital. The company went public in mid-July, raising $75 million by offering 5 million shares at $15. Its shares have been as low as $6.50 since the offering.


At least one analyst thinks there's still time to get in on the Mirium party. The Fly reported that Citigroup recently raised its price target from $21 to $30 and rated the stock a buy, as have four other analysts; one has it as a hold.

Pruritus is an unpleasant sensation that provokes the desire to scratch. Alagille syndrome is a genetic disorder that can affect the liver, heart and other parts of the body. The company estimates there are 9,000 cases in the U.S. and 14,000 in Europe.

Maralixibat was given a rare pediatric disease designation, which means the medication will get priority review if the NDA is approved. Medical experts are enthusiastic about the drug's prospects, according to an article in Invest Million.

9b9d34152c9d6dccd512ad5ff8e65f01.png

Emmanuel Gonzales, professor of pediatrics at Hospital Bicetre in Paris, said Maralixibat has shown incredible potential and that the data generated from a study of the drug were encouraging for people suffering from severe diseases.

Mirium licensed Maralixibat from Shire, which was purchased by Takeda (NYSE:TAK) about a year ago. As part of the deal, Mirum also obtained the rights to Volixibat, which is being studied as a possible treatment for nonalcoholic steatohepatitis, the most severe form of non-alcoholic fatty liver disease.

At the end of the third quarter, a total of seven of the hedge funds tracked by Insider Monkey were bullish on Mirium. The largest stake was held by Frazier Healthcare Partners, whose more than 11% position is the highest among any stocks in its portfolio.

Disclosure: The author holds no positions in the two stocks mentioned in this article.

GuruFocus 15-year anniversary promotion

The holiday season is here, and so is GuruFocus's 15-year anniversary! In order to celebrate, we are offering an exclusive holiday discount of up to 30% off on our GuruFocus Premium Membership.

Join now to get GuruFocus Premium membership for only $399/Year! In addition, save an extra $100 when you upgrade to our PremiumPlus Membership, and enjoy $100 off the price of each additional region you add to the subscription.

Don't miss out on this once-in-a-decade deal! You can sign up for the discount price by clicking this link. Happy holidays!

Read more here:


This article first appeared on GuruFocus.